secwatch.observer — SEC 8-K summary
======================================

Issuer:     DiaMedica Therapeutics Inc. (DMAC)
CIK:        0001401040
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001437749-25-016487
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DiaMedica reports Q1 net loss $7.7M; preeclampsia Phase 2 topline data expected June-July 2025
--------------------------------------------------------------------------------

- Net loss $7.7M ($0.18/sh) vs $5.2M ($0.14) in Q1 2024; R&D expense rose to $5.7M on trial expansion.
- Cash $37.3M as of Mar 31, 2025 (down from $44.1M Dec 2024); runway into Q3 2026.
- Phase 2 preeclampsia Part 1A topline results expected between 2H June and 1H July 2025; KOL event May 28.
- ReMEDy2 stroke trial enrollment progressing; interim analysis on first 200 patients expected H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401040/000143774925016487/0001437749-25-016487-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401040/000143774925016487/dmtp20250512_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-016487

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer